Description
Zepzelca (lurbinectedin) is used for the treatment of metastatic small cell lung cancer after prior platinum-based therapy. It has not been approved or studied extensively in colorectal cancer; its use in CCR would be investigational and off-label.
Mechanism of Action
Lurbinectedin is a novel alkylating agent that inhibits RNA polymerase II and transcription elongation, leading to the arrest of cancer cell proliferation.
Side Effects
Myelosuppression; nausea and vomiting; fatigue; anemia; neutropenia; thrombocytopenia
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02611024
Phase 1
Completed
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
United States, France, Germany, Italy, Spain, Switzerland